HWM_research_start_Stock Bought 7 14 25

The chart shows the growth of an initial investment of $10,000 in HWM_research_start_Stock Bought 7 14 25, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends. The portfolio is rebalanced Every 3 months.

Based on dividend-adjusted daily data since Aug 24, 2021, HWM_research_start_Stock Bought 7 14 25's average daily return is +0.21%, while the average monthly return is +4.29%. At this rate, an investment would double in approximately 1.4 years.

Historically, 59% of months were positive and 41% were negative. The best month was May 2025 with a return of +34.2%, while the worst month was Nov 2025 at -17.0%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 4 months.

On a daily basis, HWM_research_start_Stock Bought 7 14 25 closed higher 54% of trading days. The best single day was Apr 9, 2025 with a return of +13.8%, while the worst single day was Jun 9, 2022 at -12.0%.

HWM_research_start_Stock Bought 7 14 25 has an annualized alpha of 40.05%, beta of 1.52, and R2 of 0.43 versus S&P 500 Index. Calculated based on daily prices since August 24, 2021.

• This portfolio captured 279.04% of S&P 500 Index gains but only 92.28% of its losses - a favorable profile for investors.
• R2 of 0.43 means the benchmark explains less than half of this portfolio's behavior - treat beta with caution or consider switching to a more representative benchmark.

HWM_research_start_Stock Bought 7 14 25 has an expense ratio of 0.00%, meaning no management fees are charged. Below, you can find the expense ratios of the portfolio's funds side by side and easily compare their relative costs.

HWM_research_start_Stock Bought 7 14 25 ranks 22 for risk / return — below 22% of Portfolios on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk. Learn how to interpret the Sharpe ratio.

The current HWM_research_start_Stock Bought 7 14 25 Sharpe ratio is 1.63 as of Jun 13, 2026 (the value is recalculated daily), calculated over the past 12 months.

Compared to the broad market, where average Sharpe ratios range from 1.56 to 2.44, this portfolio's current Sharpe ratio falls between the 25th and 75th percentiles. This indicates that its risk-adjusted performance is in line with the majority of portfolios, suggesting a balanced approach to risk and return—likely suitable for a wide range of investors.

The chart below shows the rolling Sharpe ratio of HWM_research_start_Stock Bought 7 14 25 compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.

HWM_research_start_Stock Bought 7 14 25 provided a 0.04% dividend yield over the last twelve months.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the HWM_research_start_Stock Bought 7 14 25. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the HWM_research_start_Stock Bought 7 14 25 was 42.96%, occurring on May 11, 2022. Recovery took 253 trading sessions.

The current HWM_research_start_Stock Bought 7 14 25 drawdown is 12.66%.

The chart below shows the rolling one-month volatility.